Experimental advance of targeted medicines for chronic myeloid leukemia--review.
- Author:
Dong-Guang YANG
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Suzhou University, Suzhou 215006, China. zhangridoctor@163.com
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
administration & dosage;
Benzamides;
Drug Delivery Systems;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
Piperazines;
administration & dosage;
Protein Kinase Inhibitors;
administration & dosage;
Protein-Tyrosine Kinases;
antagonists & inhibitors;
Proto-Oncogene Proteins c-abl;
biosynthesis;
genetics;
Proto-Oncogene Proteins c-bcr;
biosynthesis;
genetics;
Pyrimidines;
administration & dosage
- From:
Journal of Experimental Hematology
2007;15(1):211-214
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder from hematopoietic stem cell disorder characterized by the consecutive expression of bcr-abl gene, and the translation product of which has enhanced tyrosine kinase activity and can activate a series of downstream signal transduction proteins and results in the occurence of CML. Although the application of imatinib (IM) makes nearly all patients with CML in chronic phase achieve a complete hematologic remission, and 90%of those treated in the early chronic phase achieve a complete cytogenetic remission, but the development of resistance to IM in the course of treatment and even in the beginning of the treatment forced people to develop new agents and to combine the new agents with IM in order to achieve better therapeutic result. This article reviews the experimental advances of targeted therapeutics in CML recent years.
